GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » Debt-to-Asset

ME Therapeutics Holding (XCNQ:METX) Debt-to-Asset : 0.00 (As of Feb. 2024)


View and export this data going back to 2023. Start your Free Trial

What is ME Therapeutics Holding Debt-to-Asset?

ME Therapeutics Holding's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was C$0.00 Mil. ME Therapeutics Holding's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was C$0.00 Mil. ME Therapeutics Holding's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Feb. 2024 was C$1.36 Mil. ME Therapeutics Holding's debt to asset for the quarter that ended in Feb. 2024 was 0.00.

ME Therapeutics Holding Debt-to-Asset Historical Data

The historical data trend for ME Therapeutics Holding's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ME Therapeutics Holding Debt-to-Asset Chart

ME Therapeutics Holding Annual Data
Trend Aug22 Aug23
Debt-to-Asset
1.89 0.06

ME Therapeutics Holding Quarterly Data
Aug22 Dec22 May23 Aug23 Nov23 Feb24
Debt-to-Asset Get a 7-Day Free Trial 0.08 0.06 0.06 0.09 -

Competitive Comparison of ME Therapeutics Holding's Debt-to-Asset

For the Biotechnology subindustry, ME Therapeutics Holding's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ME Therapeutics Holding's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ME Therapeutics Holding's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where ME Therapeutics Holding's Debt-to-Asset falls into.


ME Therapeutics Holding Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

ME Therapeutics Holding's Debt-to-Asset for the fiscal year that ended in Aug. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.04 + 0) / 0.672
=0.06

ME Therapeutics Holding's Debt-to-Asset for the quarter that ended in Feb. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0 + 0) / 1.364
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ME Therapeutics Holding  (XCNQ:METX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

ME Therapeutics Holding Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of ME Therapeutics Holding's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

ME Therapeutics Holding (XCNQ:METX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » Debt-to-Asset
Comparable Companies
Traded in Other Exchanges
Q9T:Germany
Address
177 Robson Street, Vancouver, BC, CAN, V6B 0N3
Website
https://www.metherapeutics.com
ME Therapeutics Holding Inc operates its business through ME Therapeutics. It is a preclinical-stage biotechnology company working on novel cancer-fighting drugs in the field of Immuno-Oncology (IO). It is developing preclinical data for its myeloid-targeted candidate assets using validated cancer models.

ME Therapeutics Holding (XCNQ:METX) Headlines

No Headlines